Ecor1 Capital, Llc Buys 2,222,222 Shares of Aktis Oncology (NASDAQ:AKTS) Stock

Aktis Oncology (NASDAQ:AKTS) Director Ecor1 Capital, Llc acquired 2,222,222 shares of Aktis Oncology stock in a transaction dated Monday, January 12th. The stock was bought at an average price of $18.00 per share, with a total value of $39,999,996.00. Following the completion of the purchase, the director directly owned 4,348,658 shares in the company, valued at $78,275,844. This represents a 104.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

Aktis Oncology Trading Down 2.9%

Shares of NASDAQ:AKTS traded down $0.65 during mid-day trading on Monday, reaching $21.75. 829,499 shares of the company traded hands, compared to its average volume of 39,873,640. The company has a market cap of $3.36 billion, a PE ratio of -58.78 and a beta of 1.91. Aktis Oncology has a 52 week low of $19.33 and a 52 week high of $29.16. The company has a current ratio of 0.32, a quick ratio of 0.28 and a debt-to-equity ratio of 1.00.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.